Roger-Luc Chayer (Image : AI / Gay Globe)
Medical research in the field of HIV/AIDS has been progressing for many years, moving from the absence of effective treatment to increasingly spaced-out injections that make it possible to reduce, or even stop, the daily intake of pills. But it is in 2026 that spectacular progress has been made, offering two serious avenues, one of which could eventually lead to a cure.
We have already told you about a revolutionary drug, lenacapavir, which allows people living with HIV to maintain an undetectable viral load with only two injections per year. The same drug can also be used for prevention, with a protection rate of 99%, something that would have been unimaginable just five years ago. To learn more about lenacapavir, consult this link: https://gayglobe.net/?s=L%C3%A9nacapavir
But this is not the treatment that will be discussed in this article. Rather, I will tell you about two areas of research that are producing spectacular results, one involving CAR-T cells and the other involving broadly neutralizing antibodies (bNAb).
The CAR-T approach: potentially a “functional cure”
In May 2026, a small clinical study showed that after a single administration of their own modified immune cells, two participants were able to maintain a strongly suppressed viral load without antiretroviral treatment: one for almost two years and the other for nearly one year. The CAR-T cells were designed both to recognize HIV-infected cells and to protect themselves against infection.
This is particularly interesting because the goal is no longer simply to block HIV with drugs: researchers are seeking to reprogram the patient’s immune system so that it can control the virus itself.
But great caution is needed: the study included only nine people, and only two achieved this prolonged suppression. Researchers now need to demonstrate that the method works in many more patients and for several years. It is therefore not yet an available cure.
Another major advance: neutralizing antibodies
Another very recent discovery comes from the RIO trial, presented in 2026. Researchers used broadly neutralizing antibodies (bNAb) capable of recognizing different forms of HIV. In this trial, approximately 75% of participants were able to temporarily interrupt their daily antiretroviral treatment for at least 20 weeks thanks to this strategy.
This is important because the main obstacle to an HIV cure is the latent viral reservoir: some cells retain HIV in a dormant form, invisible to drugs and the immune system. It is this reservoir that allows the virus to reappear when antiretroviral treatment is stopped. Current research is therefore seeking to awaken or eliminate these cells, and then use the immune system to destroy the virus.
But the discoveries in 2026 do not stop with these two areas of research!
A once-weekly HIV pill becomes a reality
This is probably the advance most immediately likely to change the daily lives of people living with HIV.
Results presented at AIDS 2026 show that a combination of lenacapavir and islatravir, in the form of a single tablet, can maintain viral suppression with once-weekly dosing in people who were previously on daily treatment.
Two Phase 3 trials provided the results presented in Rio, and the New England Journal of Medicine also published the results of the Phase 3 trial devoted to this combination in July 2026. This potentially means going from:
365 doses per year → 52 doses per year.
And this is not simply a matter of convenience. Once-weekly dosing could significantly reduce problems related to missed doses, stigma, and the difficulty of maintaining daily treatment.
Researchers discover that certain CD8 cells can retain an extremely powerful “memory” of HIV
This discovery is less spectacular from a media standpoint, but it could be fundamental to achieving a cure.
CD8 cells are lymphocytes capable of destroying infected cells. It has long been thought that chronic HIV infection profoundly exhausted these cells.
However, results presented in 2026 indicate that some people who have been living with HIV for a long time and whose viral load is suppressed retain a particular population of CD8 cells displaying characteristics of so-called “stem-like” cells: they can multiply rapidly and produce cells capable of effectively killing infected cells when they encounter HIV again.
This potentially changes the research strategy. Rather than seeking only to directly eliminate the HIV reservoir, researchers could learn how to awaken and amplify the patient’s own immune defenses so that they destroy cells containing the virus.
This is one of the reasons researchers are now talking more about combination therapies: awaken the hidden virus, stimulate CD8 cells, and use antibodies to eliminate infected cells.
Patients remain in remission after stem cell transplants — and new cases are helping researchers understand why
Stem cell transplantation is obviously not an acceptable HIV treatment for the general population, because it carries considerable risks and is normally performed only to treat certain cancers or serious blood disorders. But cases of people who have achieved prolonged HIV remission after transplantation continue to provide extraordinary information.
In 2026, new cases were presented, bringing to 12 and 13 the number of people considered to have achieved a cure or exceptional remission following this type of procedure, according to data presented at AIDS 2026.
Another case published in 2026 describes, in particular, a 63-year-old man who remained in HIV remission five years after receiving a stem cell transplant from a brother who possessed two copies of the CCR5Δ32 mutation, which makes cells particularly resistant to certain forms of HIV.
These patients are extremely important to research because they constitute, in a sense, natural experiments in human cure. Researchers are now seeking to reproduce the mechanism without having to subject people living with HIV to a dangerous transplant.
ADVERTISING
READ ALSO
HIV: Anti-PD-1 Immunotherapy, a Promising Path Toward Durable Remission
HIV Is No Longer a Death Sentence: End of an Era and Historic Closure in Toronto
HIV and Misinformation: Sorting Fact from Fiction on Social Media
HIV Misinformation: How False Claims and Miracle Cures Spread Online